Scandion Oncology aktie (SCOL) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Läs mer: Investera i räntebärande lån – Historisk årlig avkastning på 9,9 % (annons)

Pressmeddelanden från Scandion Oncology

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million

Today, on 20 November 2024, Scandion Oncology ("Scandion" or the "Company") announces the outcome of the exercise of warrants of series TO 2...

MFN • I förrgår 17:30

Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024

Scandion Oncology ("Scandion" or the "Company") announces that today, 14 November 2024, is the last day of trading in warrants of series TO ...

MFN • 14 Nov 08:30

Scandion Oncology – Interim Report Q3 2024

Scandion Oncology (Scandion) today announces its Interim Report Q3 2024.

MFN • 11 Nov 07:00

Invitation to Scandion Oncology webcast and conference call November 11, 2024

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 05 Nov 17:00

Scandion Oncology announces the start of the exercise period for warrants of series TO 2

Scandion Oncology ("Scandion" or the "Company") announces that the exercise period for the warrants of series TO 2, which were issued in con...

MFN • 04 Nov 08:30

Correction: Scandion Oncology announces exercise price for warrants of series TO 2

On Wednesday 30 October 2024, Scandion Oncology issued a release mistakenly stating that the exercise price for warrants of series TO 2 woul...

MFN • 31 Oct 08:30

Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology ("Scandion" or the "Company") announces that the exercise price for the warrants of series TO 2 has been determined to SEK...

MFN • 30 Oct 17:00

Scandion Oncology – Interim Report Q2 2024

Scandion Oncology (Scandion) today announces its Interim Report Q2 2024.

MFN • 29 Aug 07:00

Scandion Oncology strengthens partnering outreach

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, ...

MFN • 19 Aug 07:00

Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, ...

MFN • 16 Aug 07:00

SCANDION ONCOLOGY'S RIGHTS ISSUE REGISTERED WITH THE DANISH BUSINESS AUTHORITY

Scandion Oncology ("Scandion" or the "Company"), an innovative drug efflux pump inhibition company using biomodulation capabilities to rever...

MFN • 11 Jul 08:00

Scandion Oncology board member Michel Ducreux steps down, joins advisory board

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, ...

MFN • 01 Jul 17:30

SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE

The board of directors of Scandion Oncology (“Scandion” or the “Company”) today announces the outcome of the rights issue of units that was ...

MFN • 25 Jun 17:30

Scandion announces change of Certified Adviser to Vator Securities

Scandion Oncology (Scandion) hereby announces that the company has entered into an agreement with Vator Securities AB (“Vator Securities”) r...

MFN • 03 Jun 17:00

SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

Scandion Oncology ("Scandion" or the "Company") announces that the prospectus relating to the Company's rights issue of units (the "Rights I...

MFN • 31 May 12:00

SCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE

On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizat...

MFN • 23 May 22:30

Scandion Oncology – Interim Report Q1 2024

Scandion Oncology (Scandion) today announces its Interim Report Q1 2024.

MFN • 22 May 07:00

Invitation to Scandion Oncology webcast and conference call May 22, 2024

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 16 May 17:00

Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 13 May 07:00

Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors

The Annual General Meeting 2024 of Scandion Oncology A/S (the "Company") was held on 6 May 2024 at 2:00 p.

MFN • 06 May 16:30

Scandion Oncology to Host R&D Update May 15

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, ...

MFN • 03 May 08:00

Scandion Oncology – Notice convening the Annual General Meeting

Scandion Oncology – Notice convening the Annual General Meeting

MFN • 19 Apr 08:30

SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION

The board of directors of Scandion Oncology ("Scandion" or the "Company") has today, on 19 April 2024, resolved on the intention, subject to...

MFN • 19 Apr 08:00

BioStock: Scandion kommenterar ytterligare positiva fas IIa-data

Scandion Oncology har meddelat uppdaterade positiva interimsresultat från den tredje och sista delen av den pågående fas IIa-studien CORIST ...

Cision • 22 Mar 09:50

Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, ...

MFN • 21 Mar 07:00

Scandion Oncology - Annual Report 2023

Scandion Oncology today announces the Annual Report 2023 which is available on the company’s website.

MFN • 15 Mar 07:00

Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines bio-modulating ABCG2 and UGT1A1 to treat cancers resista...

MFN • 07 Mar 07:00

Scandion Oncologys vd till BioStock: "Our clinical study and partnering strategy are jointly progressing"

Scandion Oncologys bokslutskommuniké för 2023 fokuserar på det faktum att bolaget på ett år har levererat flera omgångar positiva data från ...

Cision • 04 Mar 08:20

Scandion Oncology – Q4 & yearend report 2023

Scandion Oncology (Scandion) today announces its Q4 & yearend report 2023.

MFN • 28 Feb 07:00

Invitation to Scandion Oncology webcast and conference call February 28, 2024

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 22 Feb 16:00

BioStock: Scandion rapporterar positiva resultat från del tre av CORIST

Scandion Oncology presenterade lovande resultat från den andra delen av CORIST-studien med SCO-101 i november förra året.

Cision • 02 Feb 09:53

Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial

Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial

MFN • 31 Jan 07:00

BioStock: Scandions vd kommenterar det positiva patentbeskedet i USA

Scandion Oncologys läkemedelskandidat SCO-101 utvärderas i två kliniska studier med slutmålet att bekämpa cancercellernas resistens mot dage...

Cision • 10 Jan 08:48

Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101

When granted, the patent will offer a very broad intellectual protection until at least 2037.

MFN • 05 Jan 08:30

CORIST part 3 topline data are expected in the second half of January 2024

The CORIST part 3 dose finding study is progressing well and topline data are expected in the second half of January 2024

MFN • 21 Dec 2023 17:30

Scandion Oncology identifies potentially effective treatment of gastric cancer

Pre-clinical studies have confirmed the potential of SCO-101 to revert gastric cancer cells’ resistance to chemotherapy, making the therapy ...

MFN • 15 Dec 2023 08:30

Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042

The new patent will cover solid crystal forms of SCO-101, which includes the form of the compound that Scandion expects to commercialize.

MFN • 29 Nov 2023 08:30

BioStock: Scandions CMO: “Vi förväntar oss toplineresultat innan årets slut”

Scandion Oncologys läkemedelskandidat SCO-101 utvärderas för närvarande i fas II-studien CORIST för behandling av kemoterapiresistent metast...

Cision • 23 Nov 2023 10:57

Scandion Oncology – Interim Report Q3 2023

Scandion Oncology (Scandion) today announces its interim report for Q3 2023.

MFN • 22 Nov 2023 08:30

Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months

Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.

MFN • 21 Nov 2023 08:30

Invitation to Scandion Oncology webcast and conference call November 22, 2023

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 15 Nov 2023 16:00

Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data.

PANTAX studies Scandion Oncology´s lead compound SCO-101 as a combination treatment in pancreatic cancer.

MFN • 16 Oct 2023 00:05

BioStock: Lars Damstrup ny CMO i Scandion Oncology

Scandion Oncology som utvecklar läkemedel riktat mot behandlingsresistent cancer, meddelade igår att Lars Damstrup ansluter till bolagets le...

Cision • 13 Sep 2023 09:51

Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer

Lars Damstrup brings extensive experience from designing and executing clinical trials in oncology.

MFN • 12 Sep 2023 07:00

BioStock: Scandion Oncology rapporterar framsteg under Q2

Scandion Oncologys Q2-rapport som presenterades under onsdagen, betonar framstegen med huvudkandidaten SCO-101 i de kliniska CORIST och PANT...

Cision • 25 Aug 2023 10:47

Scandion Oncology – Interim Report Q2 2023

Scandion Oncology (Scandion) today announces its interim report for Q2 2023.

MFN • 23 Aug 2023 08:30

Data from PANTAX trial to be presented at ESMO Congress 2023

Safety data from the PANTAX trial, studying SCO-101 in pancreatic cancer, has been accepted for poster presentation.

MFN • 17 Aug 2023 08:30

Invitation to Scandion Oncology webcast and conference call August 23, 2023

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 16 Aug 2023 08:30

BioStock: EU-patent ger Scandion utökad kommersiell exklusivitet

Det europeiska patentverket EPO avser att bevilja ett substanspatent för bioteknikbolaget Scandions ledande läkemedelskandidat SCO-101.

Cision • 19 Jul 2023 09:14

The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101

If granted, the patent will cover the commercial solid form of SCO-101 until at least 2042.

MFN • 18 Jul 2023 07:00

BioStock: Scandions vd om det nya stödet för SCO-101 i AML

En ny studie bekräftar behovet av att utveckla behandlingar som adresserar läkemedelsresistens inom blodcancersjukdomen akut myeloid leukemi...

Cision • 14 Jun 2023 08:47

BioStock: Scandion går framåt med satsningar på AML

Danska Scandion Oncology fortsätter året med satsningar på huvudkandidaten SCO-101 inom en tredje allvarlig cancerform, akut myeloid leukemi...

Cision • 26 May 2023 10:27

Scandion Oncology – Interim Report Q1 2023

Scandion Oncology (Scandion) today announces its interim report for Q1 2023.

MFN • 26 May 2023 08:30

Invitation to Scandion Oncology webcast and conference call May 26, 2023

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 19 May 2023 08:30

Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors

The Annual General Meeting 2023 of Scandion Oncology A/S (the "Company") was held on 26 April 2023 at 2:00 p.

MFN • 26 Apr 2023 17:30

BioStock: Scandions CMO kommenterar framsteg i PANTAX

Scandion Oncology har uppnått det primära målet i fas Ib-studien PANTAX – att identifiera maximalt tolererad dos av läkemedelskandidaten SCO...

Cision • 12 Apr 2023 09:55

Scandion Oncology – Notice convening the Annual General Meeting

The board of directors hereby gives notice of the annual general meeting in Scandion Oncology A/S CVR-no.

MFN • 11 Apr 2023 08:30

BioStock: Scandion Oncologys vd om expansionen till blodcancer

Scandion Oncology bibehåller ett starkt fokus på bolagets kliniska studier CORIST och PANTAX under 2023.

Cision • 03 Apr 2023 10:00

Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial)

The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapie...

MFN • 31 Mar 2023 10:00

Scandion Oncology - Annual Report 2022

Scandion Oncology (Scandion) today announces that the Annual Report 2022 is available on the company’s website.

MFN • 28 Mar 2023 08:30

Invitation to Scandion Oncology webcast and conference call March 28, 2023

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 21 Mar 2023 08:30

BioStock: Ett spännande år framöver för Scandion Oncology

Under 2022 fortsatte Scandion att göra framsteg i studierna CORIST och PANTAX med den ledande kandidaten SCO-101.

Cision • 22 Feb 2023 14:36

Scandion Oncology – Q4 & year-end report 2022

Scandion Oncology (Scandion) today announces its Q4 & year-end report 2022.

MFN • 22 Feb 2023 08:30

Invitation to Scandion Oncology webcast and conference call February 22, 2023

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current t...

MFN • 15 Feb 2023 14:30

BioStock: Scandions vd om patentutlåtandet för SCO-101

Danska Scandion Oncology har fått ett positivt utlåtande från Europeiska Patentverket avseende en patentansökan för den ledande kandidaten S...

Cision • 24 Jan 2023 09:18

BioStock: Scandions vd om förstärkningen med ny CSO

I förra veckan meddelade danska Scandion Oncology att man stärker sitt team.

Cision • 23 Jan 2023 09:17

Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101

The patent would provide protection of the commercial solid form of SCO-101 until at least 2042.

Cision • 19 Jan 2023 13:00

Scandion Oncology appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management

Jan Stenvang is co-founder of Scandion Oncology and has more than 20 years of experience in cancer research.

Cision • 18 Jan 2023 14:00

BioStock: Scandion i fronten mot läkemedelsresistent cancer

En starkt bidragande orsak till den höga dödligheten i cancer beror på att cancercellerna gradvis lyckas göra cancerbehandlingarna verknings...

Cision • 05 Jan 2023 09:27

BioStock: Bred uppgång i Scandion efter tillträdande vd och insiderköp

Den senaste månaden har Scandion valt in grundaren och tidigare vdn Nils Brünner i styrelsen, rapporterat insynsköp, och nu senast utnämnt F...

Cision • 06 Dec 2022 09:19

Scandion Oncology announces share purchase by incoming President & CEO

Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment op...

Cision • 05 Dec 2022 08:30

Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer

Bringing more than 20 years of experience as a senior level executive in the global pharmaceutical and biotech industry, Francois Martelet w...

Cision • 01 Dec 2022 08:30

Scandion Oncology announces share purchase by member of the Board of Directors

Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment op...

Cision • 23 Nov 2022 08:30

Scandion Oncology – Interim Report Q3 2022

Scandion Oncology – Interim Report Q3 2022

Cision • 16 Nov 2022 08:30

Invitation to Scandion Oncology webcast and conference call November 16, 2022

Invitation to Scandion Oncology webcast and conference call November 16, 2022

Cision • 10 Nov 2022 08:30

BioStock: Scandion kommenterar utfall från bolagsstämma

Den senaste tiden har varit händelserik för biotechbolaget Scandion Oncology.

Cision • 03 Nov 2022 10:45

Scandion Oncology Announces Results of Extraordinary General Meeting

On 28 October 2022 at 11:00 a.m. an Extraordinary General Meeting was held in Scandion Oncology A/S (the "Company").

Cision • 28 Oct 2022 12:15

Scandion Oncology – Notice convening an Extraordinary General Meeting

Scandion Oncology – Notice convening an Extraordinary General Meeting

Cision • 13 Oct 2022 17:30

Scandion Oncology initiates part 3 of the CORIST phase II trial

The first of up to 36 patients has been enrolled in part 3 of the CORIST trial in accordance with the planned timeline.

Cision • 10 Oct 2022 17:00

BioStock: Scandion Oncology kommenterar fas II-data

I slutet på förra veckan meddelade bioteknikbolaget Scandion Oncology topline-data från del två av sin fas II-studie CORIST i indikationen m...

Cision • 04 Oct 2022 08:50

Scandion Oncology announce topline results from part 2 of the CORIST phase II trial

Data from part 2 of the trial confirm the safety and tolerability of SCO-101.

Cision • 30 Sep 2022 10:30

BioStock: Skifte i Scandion Oncologys ledning

I förra veckan meddelade bioteknikbolaget Scandion Oncology, som vill förbättra förutsättningarna för behandlingsresistent cancer, om två sk...

Cision • 05 Sep 2022 14:04

Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology

Johnny Stilou, Chief Financial Officer at Scandion Oncology since July 2021, has been appointed acting CEO effective immediately.

Cision • 31 Aug 2022 11:45

Scandion Oncology announce change to its Executive Management

Maj Hedtjärn has decided to resign from her position as Chief Operating Officer and Head of R&D Operations.

Cision • 30 Aug 2022 08:55

BioStock: Stärkta finanser och klinisk utveckling under Scandion Oncologys Q2

I årets Q2-rapport belyser Köpenhamnsbaserade Scandion Oncology en framgångsrik kapitalanskaffning och ett intensivt operativt arbete.

Cision • 29 Aug 2022 10:21

BioStock: Scandion Oncology satsar på genombrott i svårbehandlad cancerform

Bioteknikbolaget Scandion Oncology ser god tolerabilitet av SCO-101 i fas Ib-studien PANTAX, som ska fastställa en säker dos av huvudkandida...

Cision • 25 Aug 2022 09:32

Scandion Oncology – Interim Report Q2 2022

Scandion Oncology – Interim Report Q2 2022

Cision • 25 Aug 2022 08:30

BioStock: Scandion Oncology vill inge hopp inom metastaserad pankreascancer

Metastaserad pankreascancer är den cancerform som har absolut sämst överlevnadsprognos.

Cision • 24 Aug 2022 08:16

Scandion Oncology receives approvals for next parts of the CORIST trial

The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022...

Cision • 19 Aug 2022 08:30

Invitation to Scandion Oncology webcast and conference call August 25, 2022

Invitation to Scandion Oncology webcast and conference call August 25, 2022

Cision • 18 Aug 2022 17:30

Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in panc...

Cision • 17 Aug 2022 08:30

BioStock: Nära förestående fas II-resultat för Scandion Oncology

Scandion Oncology utvecklar SCO-101, som har kommit som längst i bolagets pipeline inom metastaserad tjocktarmscancer.

Cision • 10 Aug 2022 08:34

Scandion Oncology announces share purchase by Board of Directors

Member of the Board of Directors has purchased shares in the company.

Cision • 08 Aug 2022 17:30

BioStock: Scandion Oncology investerar för att expandera sin tidiga pipeline

Köpenhamnsbaserade Scandion Oncology har hittills haft störst fokus på huvudkandidaten SCO-101, vilket återspeglas av att man förväntar sig ...

Cision • 08 Aug 2022 10:41

BioStock: Metastaserad tjocktarmscancer - ett angeläget problem för Scandion Oncology

Tjocktarmscancer är en av de cancerformer som är förknippat med sämst prognos, bland annat på grund av tendensen till metastasering.

Cision • 03 Aug 2022 09:06

Scandion Oncology’s rights issue registered with the Danish Business Authority

Share capital increase and updated articles of association have been registered with the Danish Business Authority.

Cision • 26 Jul 2022 17:30

Scandion Oncology announces final outcome of its rights issue

Through the issue, Scandion raises approximately SEK 75 million before deduction of issue related costs.

Cision • 04 Jul 2022 19:00

Scandion Oncology announces preliminary outcome of its rights issue

The subscription period in Scandion Oncology’s (“Scandion” or the “Company”) rights issue of shares (the “Rights Issue”) ended today, July 1...

Cision • 01 Jul 2022 22:00

Subscription period in Scandion Oncology Rights Issue of up to approximately SEK 93.7 million commences

The Rights Issue is also open for subscriptions to the public.

Cision • 16 Jun 2022 08:30

Scandion Oncology publishes prospectus in connection with the rights issue of up to approximately SEK 93.7 million

The prospectus has today been approved and registered by the Danish Financial Supervisory Authority (Finanstilsynet).

Cision • 15 Jun 2022 09:00